Anebulo Pharmaceuticals Inc (ANEB)
1.59
+0.09
(+6.00%)
USD |
NASDAQ |
Nov 22, 16:00
1.59
0.00 (0.00%)
After-Hours: 19:21
Anebulo Pharmaceuticals Enterprise Value: 37.50M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 37.50M |
| November 20, 2024 | 38.01M |
| November 19, 2024 | 38.01M |
| November 18, 2024 | 38.27M |
| November 15, 2024 | 39.79M |
| November 14, 2024 | 38.01M |
| November 13, 2024 | 38.79M |
| November 12, 2024 | 41.39M |
| November 11, 2024 | 42.42M |
| November 08, 2024 | 40.87M |
| November 07, 2024 | 36.72M |
| November 06, 2024 | 47.09M |
| November 05, 2024 | 46.31M |
| November 04, 2024 | 47.61M |
| November 01, 2024 | 46.31M |
| October 31, 2024 | 47.35M |
| October 30, 2024 | 46.57M |
| October 29, 2024 | 47.74M |
| October 28, 2024 | 46.05M |
| October 25, 2024 | 46.05M |
| October 24, 2024 | 47.87M |
| October 23, 2024 | 47.61M |
| October 22, 2024 | 46.33M |
| October 21, 2024 | 46.83M |
| October 18, 2024 | 49.46M |
| Date | Value |
|---|---|
| October 17, 2024 | 46.05M |
| October 16, 2024 | 47.61M |
| October 15, 2024 | 47.87M |
| October 14, 2024 | 46.05M |
| October 11, 2024 | 47.35M |
| October 10, 2024 | 47.09M |
| October 09, 2024 | 49.17M |
| October 08, 2024 | 47.61M |
| October 07, 2024 | 48.27M |
| October 04, 2024 | 49.17M |
| October 03, 2024 | 48.13M |
| October 02, 2024 | 49.94M |
| October 01, 2024 | 50.07M |
| September 30, 2024 | 48.65M |
| September 27, 2024 | 50.07M |
| September 26, 2024 | 47.73M |
| September 25, 2024 | 44.88M |
| September 24, 2024 | 51.11M |
| September 23, 2024 | 54.48M |
| September 20, 2024 | 76.78M |
| September 19, 2024 | 50.85M |
| September 18, 2024 | 48.77M |
| September 17, 2024 | 55.77M |
| September 16, 2024 | 51.11M |
| September 13, 2024 | 50.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
26.67M
Minimum
Oct 21 2022
204.93M
Maximum
May 21 2021
80.24M
Average
60.18M
Median
Oct 20 2023
Enterprise Value Benchmarks
| Revance Therapeutics Inc | 649.94M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.201M |
| Total Expenses (Quarterly) | 2.167M |
| EPS Diluted (Quarterly) | -0.08 |
| Earnings Yield | -18.87% |